# Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

> **NCT04332588** · PHASE1 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 25 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** [18F]FMISO PET/MRI imaging

## Key facts

- **NCT ID:** NCT04332588
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-25
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04332588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04332588, "Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04332588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*